ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Other Events
Item 8.01. Other Events.
On June27, 2017, Aralez Pharmaceuticals Inc., a company formed
under the laws of British Columbia, Canada (the Company), issued
a press release announcing that the United States District Court
for the District of New Jersey upheld the validity of two patents
owned by a subsidiary of the Company and licensed to Horizon
Pharma plc covering VIMOVO (naproxen/esomeprazole magnesium), and
that Dr.Reddys Laboratories Inc. and Dr.Reddys Laboratories Ltd.,
Mylan Pharmaceuticals Inc., Mylan Laboratories Ltd., and Mylan
Inc., and Lupin Ltd. and Lupin Pharmaceuticals Inc. would
infringe at least one of the two patents with their proposed
generic naproxen/esomeprazole magnesium products. The full text
of such press release is furnished as Exhibit99.1 to this report
and is incorporated herein by reference.
Item9.01. Financial Statements and Exhibits
(d)List of Exhibits
|
EXHIBIT NO. |
|
DESCRIPTION |
|
99.1 |
Press Release, dated June27, 2017, issued by Aralez |
Aralez Pharmaceuticals Inc. ExhibitEX-99.1 2 a17-15792_1ex99d1.htm EX-99.1 Exhibit 99.1 ARALEZ ANNOUNCES DISTRICT COURT DECISION TO UPHOLD VIMOVO (NAPROXEN/ESOMEPRAZOLE MAGNESIUM) PATENTS -Patents Covering VIMOVO Infringed by Proposed Generics Developed by Dr. Reddy’s Laboratories,…To view the full exhibit click here About ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ)
Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).
